Figure 3.

Recurrence‐free survival curves of patients in the propensity score matching cohort. (A): For individuals with tumor size ≤5 cm, the 1‐, 3‐, and 5‐year recurrence‐free survival rates were 64.4%, 45.3%, and 36.4%, respectively, in the group without adjuvant treatment and 87.2%, 65.6%, and 50.5%, respectively, in the group with adjuvant treatment. (B): For individuals with tumor size >5 cm, the 1‐, 3‐, and 5‐year recurrence‐free survival rates were 50.6%, 23.6%, and 19.7%, respectively, in the group without adjuvant treatment and 59.6%, 28.2%, and 18.8%, respectively, in the group with adjuvant treatment.

Abbreviation: PA‐TACE, postoperative adjuvant transarterial chemoembolization.